Jacobs Levy Equity Management Inc. Sells 336,189 Shares of Humana Inc. $HUM

Key Points

• Jacobs Levy Equity Management Inc. has significantly reduced its stake in Humana Inc. by 57.1% in the first quarter, now owning approximately 0.21% of the company worth about $66.97 million.
• Institutional investors and hedge funds now hold 92.38% of Humana's stock, indicating strong institutional support for the company.
• Humana recently declared a quarterly dividend of $0.885, set to be paid out on October 31st, with an annualized yield of 1.1%.

Jacobs Levy Equity Management Inc. trimmed its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 57.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 253,098 shares of the insurance provider's stock after selling 336,189 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.21% of Humana worth $66,970,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of HUM. Deutsche Bank AG increased its holdings in Humana by 18.2% in the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock valued at $160,185,000 after buying an additional 97,071 shares during the period. Janney Montgomery Scott LLC bought a new position in Humana in the 1st quarter valued at about $1,309,000. Fred Alger Management LLC bought a new position in Humana in the 4th quarter valued at about $451,000. Clearline Capital LP bought a new position in Humana in the 4th quarter valued at about $1,102,000. Finally, Envestnet Asset Management Inc. increased its holdings in Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock valued at $33,256,000 after buying an additional 2,950 shares during the period. 92.38% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on HUM. Barclays raised their target price on shares of Humana from $275.00 to $315.00 and gave the company an "equal weight" rating in a report on Friday. Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Sanford C. Bernstein raised their price target on shares of Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a research note on Friday. Bank of America raised their price target on shares of Humana from $285.00 to $312.00 and gave the company a "neutral" rating in a research note on Tuesday, September 2nd. Finally, Morgan Stanley cut their target price on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Seven analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $289.24.

Humana Trading Down 1.3%

Shares of NYSE HUM traded down $4.07 during midday trading on Friday, reaching $307.94. The stock had a trading volume of 1,504,536 shares, compared to its average volume of 1,355,815. The firm has a market cap of $37.04 billion, a price-to-earnings ratio of 23.63, a price-to-earnings-growth ratio of 1.81 and a beta of 0.44. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $369.17. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The company's 50 day moving average price is $261.46 and its 200 day moving average price is $256.30.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business's revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.1%. Humana's payout ratio is currently 27.17%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.